Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Grand Pharmaceutical Group Limited has announced the acceptance of their Phase III clinical trial application for ITM-11 in China, targeting the treatment of gastroenteropancreatic neuroendocrine tumors. The drug, which has been designated as an orphan drug by the FDA and EMA, is part of a larger portfolio of 12 innovative products the company has in the nuclear medicine anti-tumor market. With trials progressing and a strategic plan in place, Grand Pharmaceutical is emerging as a leader in the field with a comprehensive oncology diagnosis and treatment platform.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.